Literature DB >> 15153348

[Analysis of uncertainty in the economic assessment of health interventions].

Carlos Rubio-Terrés1, Erik Cobo, José Antonio Sacristán, Luis Prieto, Juan del Llano, Xavier Badia.   

Abstract

Mesh：

Year:  2004        PMID： 15153348     DOI： 10.1016/s0025-7753(04)74346-8

Source DB:  PubMed          Journal:  Med Clin (Barc)        ISSN： 0025-7753            Impact factor:   1.725


× No keyword cloud information.
  9 in total

1.  Economic assessment of fidaxomicin for the treatment of Clostridium difficile infection (CDI) in special populations (patients with cancer, concomitant antibiotic treatment or renal impairment) in Spain.

Authors:  C Rubio-Terrés; J Cobo Reinoso; S Grau Cerrato; J Mensa Pueyo; M Salavert Lletí; A Toledo; P Anguita; D Rubio-Rodríguez; M Watt; R Gani
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2015-09-25       Impact factor: 3.267

2.  Economic evaluation of Cardio inCode®, a clinical-genetic function for coronary heart disease risk assessment.

Authors:  A Ramírez de Arellano; A Coca; M de la Figuera; C Rubio-Terrés; D Rubio-Rodríguez; A Gracia; A Boldeanu; J Puig-Gilberte; E Salas
Journal:  Appl Health Econ Health Policy       Date:  2013-10       Impact factor: 2.561

3.  Economic analysis of thrombo inCode, a clinical-genetic function for assessing the risk of venous thromboembolism.

Authors:  C Rubio-Terrés; J M Soria; P E Morange; J C Souto; P Suchon; J Mateo; N Saut; D Rubio-Rodríguez; J Sala; A Gracia; S Pich; E Salas
Journal:  Appl Health Econ Health Policy       Date:  2015-04       Impact factor: 2.561

4.  Cost-effectiveness analysis of fesoterodine flexible dose in newly diagnosed patients with overactive bladder in routine clinical practice in Spain.

Authors:  Carmen Peral; Francisco Sánchez-Ballester; José M García-Mediero; Jaime Ramos; Javier Rejas
Journal:  Clinicoecon Outcomes Res       Date:  2016-09-26

5.  Economic evaluation of obinutuzumab in combination with chlorambucil in first-line treatment of patients with chronic lymphocytic leukemia in Spain.

Authors:  Luis Felipe Casado; Amparo Burgos; Eva González-Haba; Javier Loscertales; Tania Krivasi; Javier Orofino; Carlos Rubio-Terres; Darío Rubio-Rodríguez
Journal:  Clinicoecon Outcomes Res       Date:  2016-09-21

6.  Costs of adverse events associated with erlotinib or afatinib in first-line treatment of advanced EGFR-positive non-small cell lung cancer.

Authors:  Dolores Isla; Javier De Castro; Oscar Juan; Santiago Grau; Javier Orofino; Rocío Gordo; Carlos Rubio-Terrés; Darío Rubio-Rodríguez
Journal:  Clinicoecon Outcomes Res       Date:  2016-12-30

7.  Cost-effectiveness analysis of combination antifungal therapy with voriconazole and anidulafungin versus voriconazole monotherapy for primary treatment of invasive aspergillosis in Spain.

Authors:  Santiago Grau; Jose Ramon Azanza; Isabel Ruiz; Carlos Vallejo; Josep Mensa; Johan Maertens; Werner J Heinz; Jon Andoni Barrueta; Carmen Peral; Francisco Jesús Mesa; Miguel Barrado; Claudie Charbonneau; Darío Rubio-Rodríguez; Carlos Rubio-Terrés
Journal:  Clinicoecon Outcomes Res       Date:  2016-12-30

8.  Medical versus surgical treatment of first trimester spontaneous abortion: A cost-minimization analysis.

Authors:  Ana M Cubo; Zandra M Soto; Ana Haro-Pérez; M Estrella Hernández Hernández; M José Doyague; José M Sayagués
Journal:  PLoS One       Date:  2019-01-10       Impact factor: 3.240

9.  Cost-effectiveness of three echinocandins and fluconazole in the treatment of candidemia and/or invasive candidiasis in nonneutropenic adult patients.

Authors:  S Grau; J C Pozo; E Romá; M Salavert; J A Barrueta; C Peral; I Rodriguez; D Rubio-Rodríguez; C Rubio-Terrés
Journal:  Clinicoecon Outcomes Res       Date:  2015-10-13
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.